Immunovant develops autoimmune antibody drugs.
Immunovant, Inc. (IMVT) is expected to report earnings on Monday, November 9, 2026, before the open. Estimated release time 07:14 ET. Consensus EPS estimate is $-0.73.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | Jun 2026 qtr | $-0.63 | $-0.75 | — | $7.09M |
| 2026-05-20 | Mar 2026 qtr | $-0.59 | $-0.73 | — | $0 |
| 2025-11-10 | Sep 2025 qtr | $-0.72 | $-0.73 | -1.4% | $0 |
| 2025-08-11 | Jun 2025 qtr | $-0.69 | $-0.71 | -2.9% | $0 |
| 2025-05-29 | Mar 2025 qtr | $-0.71 | $-0.64 | +10.3% | $0 |
| 2025-02-06 | Dec 2024 qtr | $-0.73 | $-0.76 | -4.1% | $0 |
| 2024-11-07 | Sep 2024 qtr | $-0.61 | $-0.74 | — | $0 |
| 2024-08-06 | Jun 2024 qtr | $-0.53 | $-0.60 | -13.2% | $0 |
IMVT has beaten consensus EPS in 1 of its last 5 scored quarters.
See IMVT on the live calendar →